Loading...
Market
What will be UroGen Pharma's net product revenue from JELMYTO® by end of Q1 2025?
2
Resolution / Starting Odds
Less than $20 million • 25%
$20 million to $25 million • 25%
$25 million to $30 million • 25%
More than $30 million • 25%
UroGen Pharma financial reports
Story
UroGen Pharma Completes NDA Submission for UGN-102, Awaits FDA Decision by Q1 2025
Aug 14, 2024, 11:40 AM
UroGen Pharma has successfully completed the submission of its New Drug Application (NDA) for UGN-102, an investigational drug aimed at treating low-grade intermediate-risk non-muscle invasive bladder cancer. The company is ahead of schedule in this process and anticipates a potential FDA decision as early as the first quarter of 2025, assuming priority review. UroGen reported its 2024 second-quarter financial results, highlighting $241.3 million in cash and net product revenues of $21.8 million from JELMYTO®.
View original story
Similar markets
Below $5 billion • 25%
$5 billion to $5.5 billion • 25%
$5.5 billion to $6 billion • 25%
Above $6 billion • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Less than $25 million • 25%
$25 million to $50 million • 25%
$50 million to $75 million • 25%
More than $75 million • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $400 million • 25%
$400 million to $475 million • 25%
$475 million to $550 million • 25%
More than $550 million • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $10 billion • 25%
$10 billion to $15 billion • 25%
$15 billion to $20 billion • 25%
More than $20 billion • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $10M • 25%
$10M to $50M • 25%
$50M to $100M • 25%
More than $100M • 25%
Less than $1 billion • 25%
$1 billion - $1.5 billion • 25%
$1.5 billion - $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%